Ikena Oncology Incorporated is developing medicines tailored to patient groups with specific unmet needs. Its lead oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional factor in the Hippo signaling pathway. The company is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway, IK-175, an oral inhibitor of aryl hydrocarbon receptor, and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. Ikena Oncology was incorporated in 2016 and is headquartered in Boston, MA.
What is Ikena Oncology's quote symbol?
What is the 52 week high and low for Ikena Oncology (NASDAQ: IKNA)?
How much is Ikena Oncology stock worth today?
How much is Ikena Oncology's stock price per share?
What is Ikena Oncology's Market Cap?